Back Login to subscribe 🔔 Set Alert

AZN AstraZeneca PLC

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	AstraZeneca shares are trading lower after the company announced it entered into an exclusive global license agreement with Dizal, where it will pay $600 million upfront and up to $900 million in milestones and royalties.	96.64%
	AstraZeneca Announced Earlier It Entered Exclusive Global License Agreement With Dizal For Novel Oral EGFR Inhibitor Zegfrovy For Lung Cancer; AstraZeneca To Pay $600M Upfront, Up To $900M In Milestones, Plus Royalties	87.63%
	Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain	75.36%
	Ionis And AstraZeneca's CARDIO-TTRansform Phase 3 Trial Of Eplontersen Misses Primary Endpoint In Transthyretin-Mediated Amyloid Cardiomyopathy Patients Compared With Placebo	90.42%
	Sino Biopharma Accelerates Global Growth With GSK, AstraZeneca Partnerships	90.75%
	'AstraZeneca, Daiichi Near UK Price Deal for Breast Cancer Drug' - Bloomberg	82.89%
	Helix Partners With AstraZeneca Over Access To Phenotyped GenoSphere Cohorts	86.7%
	Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance	75.09%
	AstraZeneca shares are trading higher after the company announced it entered into a strategic collaboration agreement with Abbisko Therapeutics to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer. The company and CSPC Pharmaceutical Group entered into an agreement to use the siRNA drug discovery platform to develop novel small nucleic acid drug candidates.	94.94%
	CSPC Pharmaceutical Earlier Announced Strategic Research Collaboration, Option, License Agreement With AstraZeneca To Develop Novel Small Nucleic Acid Drug Candidates Using Proprietary SiRNA Drug Discovery And Extrahepatic Targeted Delivery Platforms	82.52%

1
2
›